Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY RE-HIT: Ianalumab retreatment in adults with prior response in ITP or warm autoimmune hemolytic anemia
2024-518231-11-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 2, open-label trial of ianalumab in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) (2 cohorts), sponsored by Novartis. Primary endpoints: ITP: Treatment failure free at 12 months after start of second ianalumab course and wAIHA: Durable hemoglobin response between week 9 and week 25. Started Dec 2025; status: completed.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2024-518231-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518231-11-00.